Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 3 clients • 8 examiners • 5 art units • 0 of 8 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
ArentFox Schiff, LLP & DFCI has 9 pending office actions in Biotechnology & Pharmaceuticals and 33400 career applications. The current docket can be viewed against a broad application history in this technology area.
The resolved allowance rate is 87.96%, with an average of 3.27 office actions per allowance. Successful resolution is common in the reported record, but allowance generally follows several examination actions. Practitioners should prepare for iterative claim development and sustained attention to technical support.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (12%) |
| §112 only | 1 (12%) |
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 3 (38%) |
| No statute on record | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
| CHICKS, ASHLI ARIANA | 1 | 60.0% | +51.0% |
| HUI, SAN MING R | 1 | 59.6% | +20.0% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.1% | +41.1% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 182d overdue |
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | PECKHAM, RICHARD GRANT | 42d overdue |
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | 13d |
| 18576068 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 AND USES THEREOF | NEAGU, IRINA | — |
| 18557225 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 182d overdue |
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | PECKHAM, RICHARD GRANT | 42d overdue |
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | 13d |
| 18281861 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | CHICKS, ASHLI ARIANA | 54d |
| 18576068 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 AND USES THEREOF | NEAGU, IRINA | — |
| 18557225 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DEKARSKE, MADELINE MCGUIRE | — |
| 18280877 | EP300 DEGRADER AND USES THEREOF IN NEUROBLASTOMA | HUI, SAN MING R | — |
| 17621057 | HCK DEGRADERS AND USES THEREOF | LADD, CAROLYN LOUISE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| DANA-FARBER CANCER INSTITUTE, INC. | 6 |
| Yeda Research And Devlopment Co. Ltd. | 1 |
| NEOMORPH, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| 1622 | 2 |
| 1627 | 2 |
| 1626 | 1 |
| 1621 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18576068 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | NEAGU, IRINA | 1629 | §103§112 | Non-Final OA | — | Pending | Jan 02, 2024 |
| 18557225 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | DEKARSKE, MADELINE MCGUIRE | 1622 | Other | Final Rejection | — | Pending | Oct 25, 2023 |
| 18281861 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | Yeda Research And Devlopment Co. Ltd. | CHICKS, ASHLI ARIANA | 1626 | §102Other | Non-Final OA | 54d | Pending | Sep 13, 2023 |
| 18280877 | EP300 DEGRADER AND USES THEREOF IN NEUROBLASTOMA | DANA-FARBER CANCER INSTITUTE, INC. | HUI, SAN MING R | 1627 | §112Other | Final Rejection | — | Pending | Sep 07, 2023 |
| 18031077 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Neomorph, Inc. | TOWNSLEY, SARA ELIZABETH | 1629 | §112DP | Non-Final OA | 13d | Pending | Apr 10, 2023 |
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. | HEITMEIER, KENDALL NICOLE | 1621 | §102§103§112 | Final Rejection | 182d overdue | Pending | Aug 23, 2022 |
| 17621057 | HCK DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | LADD, CAROLYN LOUISE | 1622 | DP | Final Rejection | — | Pending | Dec 20, 2021 |
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | PECKHAM, RICHARD GRANT | 1627 | §102§112 | Final Rejection | 42d overdue | Pending | Feb 01, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial88.0% of resolved applications prosecuted by Arentfox Schiff, LLP & Dfci were allowed, across 33,400 applications in USPTO records.
3.27 office actions per allowed application on average.
8 pending office actions as of October 2026, for 3 clients, before 8 examiners in 5 art units.
